Within-person variability of urinary 6β-hydroxycortisol to urinaryl ratios in Caucasian women

Steroids

Volumn 69, Issue 1, 2004, Pages 67-70

  Chen, Zhi ^a,d   Dunning, Lisa A ^b   Anderson, Kristin E ^c   Holtzman, Jordan L ^b   Zheng, Wei ^a,c  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d CHINA MEDICAL UNIVERSITY   (China)

Author keywords

6 Hydroxycortisol to cortisol ratios; Biomarkers; CYP3A4; Epidemiology; Steroid

Indexed keywords

6BETA HYDROXYHYDROCORTISONE; BIOLOGICAL MARKER; CYTOCHROME P450 3A4; HYDROCORTISONE;

ADULT; ARTICLE; CAUCASIAN; CONTROLLED STUDY; CORRELATION ANALYSIS; CORRELATION COEFFICIENT; DIAGNOSTIC KIT; ENZYME ACTIVITY; FEMALE; HORMONE DETERMINATION; HUMAN; HYDROCORTISONE URINE LEVEL; IMMUNOASSAY; NORMAL HUMAN; RADIOIMMUNOASSAY; RISK; URINALYSIS;

EID: 0347359108     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.steroids.2003.10.004     Document Type: Article

References (26)

1. Lewis DFV. Cytochrome P450: structure, function, and metabolism. London: Taylor & Francis; 1996. p. 15-167.
2. Huang Z., Guengerich F.P., Kaminsky L.S. 16α-Hydroxylation of estrone by human cytochrome P450 3A4/5. Carcinogenesis. 19:1998;867-872.
3. Yamazaki H., Shimada T. Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch. Biochem. Biophys. 346:1997;161-169.
4. Thomas H.V., Reeves G.K., Key T.J. Endogenous estrogen and post-menopausal breast cancer: a quantitative review. Cancer Causes Control. 8:1997;922-928.
5. Ross RK, Schottenfeld D. Prostate cancer. In: Schottenfeld D Fraumeni Jr JF, editors. Cancer epidemiology and prevention. 2nd ed. Oxford University Press; 1996.
6. Rebeck T.R., Jaffe J.M., Walker A.H., Wein A.J., Malkowicz B. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J. Natl. Cancer Inst. (Bethesda). 90:1998;1225-1229.
7. Paris P.L., Kupelian P.A., Hall J.M.et al. Association between a CPY3A4 genetic variant and clinical presentation in African-American prostate cancer patients. Cancer Epiemiol. Biomark. Prev. 8:1999;901-905.
8. Felix C.A., Walker A.H., Lange B.J., Williams T.M., Winick N.J., Cheung N.-K.V. Association of CYP3A4 genotype with treatment-related leukemia. Proc. Natl. Acad. Sci. U.S.A. 95:1998;13176-13181.
9. Sata F., Sapone A., Elizondo G.et al. Pharmacogenetics and genomics: CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin. Pharmacol. Ther. 67:2000;48-56.
10. Westlind A., Lofberg L., Tindberg N., Andersson T.B., Ingelman-Sundberg M. Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5′-upstream regulatory region. Biochem. Biophys. Res. Commun. 259:1999;201-205.
11. Rebbeck T.R. More about: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J. Natl. Cancer Inst. 92:2000;76.
12. Dienvenu T., Rey E., Pons G., D'Athis P., Olive G. A simple noninvasive procedure for the investigation of cytochrome P450 IIIA dependent enzymes in humans. Int. J. Clin. Pharmacol. Ther. Toxicol. 29:1991;441-445.
13. Joellenbeck L., Qian Z., Zarba A., Groupman J.D. Urinary 6β-hydroxycortisol/cortisol ratios measured by high-performance chromatography for use as a biomarker for the human cytochrome P-450 3A4aaa. Cancer Epiemiol. Biomark. Prev. 1:1992;567-572.
14. Saenger P. 6β-Hydroxycortisol in random urine samples as an indicator or enzyme induction. Clin. Pharmacol. Ther. 34:1983;818-821.
15. Ohnhaus E.E., Breckenridge A.M., Park B.K. Urinary excretion of 6β-hydroxycortisol and the time course measurement of enzyme induction in man. Eur. J. Clin. Pharmacol. 36:1989;39-46.
16. Dolara P., Lodovici M., Salvadori M., Zaccara G., Muscas G.C. Urinary 6β-OH-cortisol and paracetamol metabolites as a probe for assessing oxidation and conjugation of chemicals in humans. Pharmacol. Res. Commun. 19:1987;261-273.
17. Ged C., Rouillon J.M., Pichard L.et al. The increase in urinary excretion of 6β-hydroxycortisol as a marker of human hepatic cytochrome P450111A induction. Br. J. Clin. Pharmacol. 28:1989;373-387.
18. Zheng W., Jin F., Dunning L.A., Shu X.O., Dai Q., Wen W.Q.et al. Epidemiological study of urinary 6β-hydroxycortisol to cortisol ratios and breast cancer risk. Cancer Epidemiol. Biomark. Prev. 10:2001;237-242.
19. Forthofer RN, Lee FS. Introduction to biostatistics: a guide to design, analysis, and discovery. California: Academic Press Inc.; 1995. p. 74-5, 82-5.
20. Burstein A.H., Reiss W.G., Kaintor E., Anderson G.D. Cytochrome P450 3A4 activity in premenopausal and postmenopausal women based on 6β- hydroxycortisol: cortisol ratios. Pharmacotherapy. 18:1998;1271-1276.
21. Armstrong BK, White E, Saracci R. Principles of exposure measurement in epidemiology. New York: Oxford Medical Publications; 1992. p. 49-74.
22. Chen C., Malone K.E., Prunty J., Daling J.R. Measurement of urinary estrogen metabolites using a monoclonal enzyme-linked immunoassay kit: assay performance and feasibility for epidemiological studies. Cancer Epidemiol. Biomark. Prev. 5:1996;727-732.
23. Chen Z., Zheng W., Dunning L.M., Anderson K.G., Parrish R.S., Holtzman J.L. Within-person variability of the ratios of urinary 2-hydroxyestrone to 16α-hydroxyestrone in Caucasian women. Steroids. 64:1999;856-859.
24. McQuilkin S.H., Nierenberg D.W., Bresnick E. Analysis of within-subject variation of caffeine metabolism when used to determine cytochrome P4501A2 and N-acetyltransferase-2 activities. Cancer Epidemiol. Biomark. Prev. 4:1995;139-146.
25. Watkins P.B., Murry S.A., Winkelman L.G., Heuman D.M., wrighton S.A., guzelian P.S. Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450: studies in rats and patients. J. Clin. Invest. 83:1989;688-697.
26. May D.G., Arns P.A., Richards W.O.et al. The disposition of dapsone in cirrhosis. Clin. Pharmacol. Ther. 51:1992;689-700.